Analysts think ACRS stock price could increase by 117%
Dec 09, 2025, 12:25 PM
-8.81%
What does ACRS do
Aclaris Therapeutics, a biopharmaceutical company based in Wayne, Pennsylvania, focuses on developing novel drugs for dermatology and immunology, with key candidates including ATI-1777 and Zunsemetinib. Founded in 2015, it employs 91 staff and utilizes its KINect platform for drug discovery.
8 analysts think ACRS stock price will increase by 117.02%. The current median analyst target is $7.14 compared to a current stock price of $3.29. The lowest analysts target is $2.02 and the highest analyst target is $16.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.